Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Cited by (7,499)

Items 1,001–1,100 of 7,499

1. Angiotensin II Type 1 and Type 2 Receptors Play Opposite Roles in Regulating the Barrier Function of Kidney Glomerular Capillary Wall
   Koichi Suzuki, Gi Dong Han, Naoko Miyauchi, Taeko Hashimoto, Takeshi Nakatsue, Yumiko Fujioka, Hiroko Koike, Fujio Shimizu, Hiroshi Kawachi · 2007 · American Journal Of Pathology
2. A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients
   George L. Bakris · 2001 · Archives of Internal Medicine
3. The importance of the intrarenal renin–angiotensin system
   Juan Carlos Q. Velez · 2008 · Nature Reviews Nephrology
4. Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes
   R Estacio, Joseph R Coll, Zung Vu Tran, Robert W. Schrier · 2006 · American Journal of Hypertension
5. Recent advances in diabetic nephropathy
   Sally M. Marshall · 2004 · Postgraduate Medical Journal
6. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
   Y. Miao, Daniela Dobre, Hiddo J.L. Heerspink, Barry Morton Brenner, Mark Emmanuel Cooper, H.-H. Parving, S. Shahinfar, Diederick E. Grobbee, Dick de Zeeuw · 2010 · Diabetologia
7. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure – meta-analyses of randomized trials
   Costas Thomopoulos, Gianfranco Parati, Alberto Zanchetti · 2016 · Journal of Hypertension
8. Angiotensin II Receptor Blockade
   Andreï Forclaz, Marc P Maillard, Jürg Nussberger, Hans Rudolf Brunner, Michel Burnier · 2003 · Hypertension
9. Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor–mediated kidney fibrosis
   Jian-dong Zhang, Mehul B. Patel, Robert Griffiths et al. · 2014 · Journal of Clinical Investigation
10. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications
    Vaibhav B. Patel, Nirmal Parajuli, Gavin Y. Oudit · 2013 · Clinical Science
11. Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
    Sabrina Scilletta, Maurizio Di Marco, Nicoletta Miano, Agnese Filippello, Stefania Di Mauro, Alessandra Scamporrino, Marco Musmeci, Giuseppe Coppolino, Francesco Di Giacomo Barbagallo, Giosiana Bosco et al. · 2023 · Biomolecules
12. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
    Na Wang, Chun Zhang · 2024 · International Journal of Molecular Sciences
13. Treatment for patients with the metabolic syndrome
    Henry N. Ginsberg · 2003 · The American Journal of Cardiology
14. The Family Investigation of Nephropathy and Diabetes (FIND): design and methods.
    W. Knowler, J. Coresh, R. Elston, B. Freedman, S. Iyengar, P. Kimmel, J. Olson, R. Plaetke, J. Sedor, M. Seldin · 2005 · Journal of diabetes and its complications
15. Angiotensin II Blockade and Renal Protection
    Hiroyuki Kobori, Hirohito Mori, Tsutomu Masaki, Akira Nishiyama · 2013 · Current Pharmaceutical Design
16. Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease
    Katherine R. Tuttle, Janet B. McGill, Douglas J. Haney, Toni E. Lin, Pamela W. Anderson · 2007 · Clinical Journal of the American Society of Nephrology
17. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective
    James T. Lane · 2004 · American Journal of Physiology-Renal Physiology
18. Mortality Rates in Trials of Subjects With Type 2 Diabetes
    Ebrahim Barkoudah, Hicham Skali, Hajime Uno, Scott David Solomon, Marc Alan Pfeffer · 2012 · Journal of the American Heart Association
19. Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers
    Ji‐Guang Wang, Yan Li, Stanley S. Franklin, Michel E. Safar · 2007 · Hypertension
20. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?
    Dick de Zeeuw · 2004 · Kidney International
21. Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy
    Maria Luiza Caramori, Paola Fioretto, Michael S. Mauer · 2006 · Journal of the American Society of Nephrology
22. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study
    Wada, Takashi, Inagaki, Masaya, Yoshinari, Toru, Terata, Ryuji, Totsuka, Naoko, Gotou, Miki, Hashimoto, Gaia · 2021 · Clinical and Experimental Nephrology
23. Potential New Therapeutic Agents for Diabetic Kidney Disease
    Faruk Hilmi Turgut, Warren Kline Bolton · 2010 · American Journal of Kidney Diseases
24. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years
    Claire Alexandra Lawson, Samuel Seidu, Francesco Zaccardi, Gerry Patrick McCann, Umesh T. Kadam, Melanie Jane Davies, Carolyn S.P. Lam, Hiddo J.L. Heerspink, Kamlesh K. Khunti · 2021 · EClinicalMedicine
25. Nox4 as a novel therapeutic target for diabetic vascular complications
    Dongxia Wang, Jiaying Li, Gang Luo, Juan Zhou, Ning Wang, Shanshan Wang, Rui Zhao, Xin Cao, Yuxia Ma, Gang Liu et al. · 2023 · Redox Biology
26. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection
    Norberto Perico, Ariela Benigni, Giuseppe Remuzzi · 2008 · Nature Reviews Drug Discovery
27. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis
    Steven D. Crowley, Matthew P. Vasievich, Phillip Ruiz, Samantha Gould, Kelly K. Parsons, A. Kathy Pazmino, Carie S. Facemire, Benny J. Chen, Hyung‐Suk Kim, Trinh T. Tran et al. · 2009 · Journal of Clinical Investigation
28. 3: Preventing complications of diabetes
    Katherine L Bate, George Jerums · 2003 · The Medical Journal of Australia
29. From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria
    Paul E. de Jong, Barry Morton Brenner · 2004 · Kidney International
30. Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes
    Weil, E. Jennifer, Fufaa, Gudeta, Jones, Lois I., Lovato, Tracy, Lemley, Kevin V., Hanson, Robert L., Knowler, William C., Bennett, Peter H., Yee, Berne, Myers, Bryan D. et al. · 2013 · Diabetes
31. High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo
    Ernest Kiswaya Sumaili, Eric P. Cohen, Chantal Vuvu Zinga · 2009 · BMC Nephrology
32. Angiotensin II has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli
    Daria V. Ilatovskaya, Oleg Palygin, V. I. Chubinskiy-Nadezhdin · 2014 · Kidney International
33. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT 1 receptor antagonist
    Yan Zhang, Dilip K. Deb, Juan Kong, Gang Ning, Yurong Wang, George Qian Li, Yunzi Chen, Zhongyi Zhang, Stephen A. Strugnell, Yves Sabbagh et al. · 2009 · American Journal of Physiology-Renal Physiology
34. Oxidative stress and diabetic vascular complications
    Seok Man Son, Matthew Keith Whalin, Harrison Dg, W. Robert Taylor, Kathy K. Griendling · 2004 · Current Diabetes Reports
35. RTN1 mediates progression of kidney disease by inducing ER stress
    Ying Fan, Wenzhen Xiao, Zhengzhe Li, Xuezhu Li, Peter Y. Chuang, Belinda Jim, Weijia Zhang, Chengguo Wei, Niansong Wang, Weiping Jia et al. · 2015 · Nature Communications
36. Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)
    Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, Paul Audhya, George L. Bakris, Melanie P. Chin, Melissa Krauth, Hiddo J.L. Heerspink, Colin J. Meyer, John J.V. McMurray et al. · 2013 · American Journal of Nephrology
37. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy
    Jan Galle, Edzard Schwedhelm, Sabine Pinnetti, Rainer H. Böger, Christoph Wanner, on behalf of the VIVALDI investigators · 2008 · Nephrology Dialysis Transplantation
38. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
    Hajime Nagasu, Yuichiro Yano, Hiroshi Kanegae, Hiddo J.L. Heerspink, Masaomi Nangaku, Yosuke Hirakawa, Yuka Sugawara, Naoki Nakagawa, Yuji Tani, Jun Wada et al. · 2021 · Diabetes Care
39. ACE2: A novel therapeutic target for cardiovascular diseases
    Shant Der Sarkissian, Matthew J. Huentelman, Jillian M. Stewart, Michael J. Katovich, Mohan K. Raizada · 2005 · Progress in Biophysics and Molecular Biology
40. High glucose and renin release: the role of succinate and GPR91
    János Peti‐Peterdi · 2010 · Kidney International
41. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report
    Bruce L. Riser, Pedro Cortés, Mark O. DeNichilo, Poornima V. Deshmukh, Parminder S. Chahal, Ali Kareem Mohammed, Jerry Yee, Dorothy Kahkonen · 2003 · Kidney International
42. Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect
    Ling Hong Yu, Wayne A. Border, Ian Anderson, Matthew Mccourt, Yufeng Huang, Nancy A. Noble · 2004 · Kidney International
43. Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR
    Mahboob Rahman, Charles E. Ford, Jeffrey A. Cutler, Barry R. Davis, Linda B. Piller, Paul Kieran Whelton, Jackson T. Wright, Joshua I. Barzilay, Clinton D. Brown, Pedro J. Colon et al. · 2012 · Clinical Journal of the American Society of Nephrology
44. Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis
    Kirsten Howard, Sarah White, Glenn P. Salkeld, Stephen Peter McDonald, Jonathan C. Craig, Steven James Chadban, Alan Cass · 2009 · Value in Health
45. Renal expression of COX-2, ANG II, and AT1receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory
    Anderson Ricardo Roman Gonçalves, Clarice Kazue Fujihara, Ana Lúcia Mattar · 2004 · American Journal of Physiology-Renal Physiology
46. Kidney and hypertension
    Adamczak, Marcin, Zeier, Martin, Dikow, Ralf, Ritz, Eberhard · 2002 · Kidney International
47. Social Determinants of Health: Addressing Unmet Needs in Nephrology
    Yoshio N. Hall · 2018 · American Journal of Kidney Diseases
48. Chronic kidney disease
    William Guy Herrington, Parminder K. Judge, Morgan Erika Grams, Christoph Wanner · 2025 · The Lancet
49. CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Racial and Ethnic Disparities in End‐Stage Kidney Failure—Survival Paradoxes in African‐Americans
    Lawrence Y C Agodoa, Paul W. Eggers · 2007 · Seminars in Dialysis
50. Renal Function Trajectory Is More Important than Chronic Kidney Disease Stage for Managing Patients with Chronic Kidney Disease
    Steven Jay Rosansky · 2012 · American Journal of Nephrology
51. Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association
    Alain Cohen Solal, Florence Beauvais, Damien Logeart · 2008 · Journal of Cardiac Failure
52. Diabetic nephropathy: Linking histology, cell biology, and genetics
    Sharon G. Adler · 2004 · Kidney International
53. Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease
    Andrew John Palmer, Lieven Annemans, Stéphane Roze, Mark Lamotte, Pablo Lapuerta, Roland K. Chen, Sylvie Gabriel, Paulo Carita, Roger A. Rodby, Dick de Zeeuw et al. · 2004 · Diabetes Care
54. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity
    Helmy M. Siragy, Jiqian Huang · 2008 · Experimental Physiology
55. Treatment of Hypertension in Patients With Diabetes
    James R. Sowers · 2004 · Archives of Internal Medicine
56. Renal Function Preservation in Type 2 Diabetes Mellitus Patients With Early Nephropathy: A Comparative Prospective Cohort Study Between Primary Health Care Doctors and a Nephrologist
    Héctor R. Martínez–Ramírez, Basilio Jalomo‐Martínez, Laura Cortés–Sanabria, Enrique Rojas Campos, Graciela Barragán, Gilberto Alfaro, Alfonso Martin Cueto-Manzano · 2005 · American Journal of Kidney Diseases
57. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan
    Naoki Kashihara, Shun Kohsaka, Eiichiro Kanda, Suguru Okami, Toshitaka Yajima · 2019 · Kidney International Reports
58. Nephrotic Syndrome
    Seth Anthony Politano, Gates B. Colbert, Nida Hamiduzzaman · 2020 · Primary Care Clinics in Office Practice
59. The Role of SIRT1 in Diabetic Kidney Disease
    Rabi Yacoub, Kyung Lee, Cijiang He · 2014 · Frontiers in Endocrinology
60. Urinary fatty acid binding protein in renal disease
    Atsuko Kamijo‐Ikemori, Takeshi Sugaya, Kenjiro Kimura · 2006 · Clinica Chimica Acta
61. Epidemiology and risk factors for chronic kidney disease.
    W. Mcclellan · 2005 · The Medical clinics of North America
62. Remission of renal disease: recounting the challenge, acquiring the goal
    Barry Morton Brenner · 2002 · Journal of Clinical Investigation
63. Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation
    Stephen I‐Hong Hsu, William G. Couser · 2003 · Journal of the American Society of Nephrology
64. A Low-Iron-Available, Polyphenol-Enriched, Carbohydrate-Restricted Diet to Slow Progression of Diabetic Nephropathy
    Francesco S. Facchini, Kami L. Saylor · 2003 · Diabetes
65. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure.
    Peter A McCullough, Joseph Kuncheria, Vandana S Mathur · 2003 · PubMed
66. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature
    George, Cindy, Echouffo-Tcheugui, Justin B., Jaar, Bernard G., Okpechi, Ikechi G., Kengne, Andre P. · 2022 · BMC Medicine
67. Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
    Jeffrey L. Probstfield, Kevin D. O’Brien · 2009 · The American Journal of Cardiology
68. Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets
    Jens van de Wouw, Michelle Broekhuizen, Oana Sorop, Jaap A. Joles, Marianne Christina Verhaar, Dirk Jan Duncker, A.H. Jan Danser, Daphne Merkus · 2019 · Frontiers in Physiology
69. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
    Hiddo J.L. Heerspink, Rajiv Agarwal, George L. Bakris, David Z.I. Cherney, Carolyn S.P. Lam, Brendon Lange Neuen, Pantelis A. Sarafidis, Katherine R. Tuttle, Christoph Wanner, MEIKE DANIELA BRINKER et al. · 2024 · Nephrology Dialysis Transplantation
70. Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats
    Masateru Taira, Hiroe Toba, Masafumi Murakami, Ikumi Iga, Ryoko Serizawa, Shoko Murata, Miyuki Kobara, Tetsuo Nakata · 2008 · European Journal of Pharmacology
71. Activation of the renal renin-angiotensin system in diabetes--new concepts
    János Peti‐Peterdi, Jung Julie Kang, Ildikó Toma · 2008 · Nephrology Dialysis Transplantation
72. Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
    L. Gregg, S. Hedayati · 2018 · American Journal of Kidney Diseases
73. Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil
    Bakris, George L., Sica, Domenic, White, William B., Cushman, William C., Weber, Michael A., Handley, Alison, Song, Eric, Kupfer, Stuart · 2012 · The American Journal of Medicine
74. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar
    Chi Pang Wen, Kunihiro Matsushita, Josef Coresh, Kunitoshi Iseki, Muhammad Islam, Ronit Katz, William McClellan, Carmen Alicia Peralta, Haiyan Wang, Dick de Zeeuw et al. · 2014 · Kidney International
75. Defining end-stage renal disease in clinical trials: a framework for adjudication: Table 1.
    Rajiv Agarwal · 2015 · Nephrology Dialysis Transplantation
76. High burden and unmet patient needs in chronic kidney disease
    Vipan Sood, Braun, Hogue, Lieberman, Catherine Copley‐Merriman · 2012 · International Journal of Nephrology and Renovascular Disease
77. Coming full circle in diabetes mellitus: from complications to initiation
    Brooke E. Harcourt, Sally A. Penfold, Josephine Maree Forbes · 2013 · Nature Reviews Endocrinology
78. Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy
    Akira Mima, Takeshi Matsubara, Hidenori Arai, Hideharu Abe, Kojiro Nagai, Hiroshi Kanamori, Eriko Sumi, Toshikazu Takahashi, Noriyuki Iehara, Atsushi Fukatsu et al. · 2006 · Laboratory Investigation
79. Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes
    Seema Basi, James D. Lewis · 2006 · American Journal of Kidney Diseases
80. Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria
    Velho, Gilberto, Bouby, Nadine, Hadjadj, Samy, Matallah, Nadia, Mohammedi, Kamel, Fumeron, Frédéric, Potier, Louis, Bellili-Munoz, Naïma, Taveau, Christopher, Alhenc-Gelas, François et al. · 2013 · Diabetes Care
81. Stem Cell Therapies in Kidney Diseases: Progress and Challenges
    Cinzia Rota, Marina Morigi, Barbara Imberti · 2019 · International Journal of Molecular Sciences
82. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes
    George L. Bakris, Luis Miguel Ruilope, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Peter R Rossing, Linda P. Fried, Prabir Roy‐Chaudhury, Pantelis A. Sarafidis, Christiane Ahlers et al. · 2022 · Kidney International
83. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation
    Laura Gabriela Sánchez‐Lozada, Edilia Tapia, Richard J. Johnson, Bernardo Rodríguez‐Iturbe, Jaime Herrera-Acosta · 2003 · Kidney International
84. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers
    Marsha A. Raebel, David L. McClure, Steven R. Simon, K. Arnold Chan, Adrianne C. Feldstein, Susan E. Andrade, Jennifer Elston Lafata, Douglas W. Roblin, Robert Lowell Davis, Margaret J. Gunter et al. · 2006 · Pharmacoepidemiology and Drug Safety
85. ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy
    Hans‐Henrik Parving, Dick de Zeeuw, Mark Emmanuel Cooper et al. · 2008 · Journal of the American Society of Nephrology
86. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension
    Andreas J. Flammer, Frank Hermann, Peter Wiesli, Beat Schwegler, Rémy Chenevard, David Hürlimann, Isabella Sudano, Steffen Gay, Michel Neidhart, Walter Riesen et al. · 2007 · Journal of Hypertension
87. PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose
    Usha Panchapakesan, Siska Sumual, Carol A. Pollock, Xinming Chen · 2005 · American Journal of Physiology-Renal Physiology
88. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial
    Carl J. Pepine, Eileen Mary Handberg, R COOPERDEHOFF · 2004 · ACC Current Journal Review
89. Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients
    Carmine Savoia, Rhian M. Touyz, Dierk Endemann, Qian Pu, Eun Ae Ko, Carolina De Ciuceis, Ernesto L. Schiffrin · 2006 · Hypertension
90. Increased Renal Arterial Resistance Predicts the Course of Renal Function in Type 2 Diabetes With Microalbuminuria
    R. Nosadini, Mario Velussi, Enrico Brocco, Cataldo Abaterusso, Andrea Carraro, Francesco Piarulli, Giuseppe Morgia, Andrea Ercole Satta, Rossana Faedda, Avinash Abhyankar et al. · 2006 · Diabetes
91. Urinary Transforming Growth Factor-β Excretion in Patients With Hypertension, Type 2 Diabetes, and Elevated Albumin Excretion Rate
    Christine A. Houlihan, Aysel Akdeniz, Con Tsalamandris, Mark Emmanuel Cooper, George Jerums, Richard E. Gilbert · 2002 · Diabetes Care
92. 2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations
    Lawrence R. Krakoff, Robert L. Gillespie, Keith C. Ferdinand, Icilma V. Fergus, Ola Akinboboye, Kim Allan Williams Sr, Mary Norine Walsh, C. Noel Bairey Merz, Carl J. Pepine · 2014 · Journal of the American College of Cardiology
93. Diuretic use in renal disease
    Domenic A. Sica · 2011 · Nature Reviews Nephrology
94. Validating a case definition for chronic kidney disease using administrative data
    Paul Everett Ronksley, Marcello A. Tonelli, Hude Quan, Braden Manns, Matthew Thomas James, Fiona M Clement, Susan M. Samuel, Robert Ross Quinn, Pietro Ravani, S. Brar et al. · 2011 · Nephrology Dialysis Transplantation
95. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
    Carlo Garofalo, Silvio Borrelli, Maria Liberti, Michele Andreucci, Giuseppe Conte, Roberto Minutolo, Michele Provenzano, Luca De Nicola · 2019 · Medicina
96. Pathomechanisms of Diabetic Kidney Disease
    Satyesh K. Sinha, Susanne B. Nicholas · 2023 · Journal of Clinical Medicine
97. The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress
    José B. Lopes de Faria, Kamila Cristina Silva, Jacqueline M. Lopes de Faria · 2011 · Hypertension Research
98. An update on the referral pattern of patients with end-stage renal disease
    Norbert Hendrik Lameire, Jean‐Pierre Wauters, José Luis Teruel, Wim Van Biesen, Raymond Camille Vanholder · 2002 · Kidney International
99. Angiotensin receptor blockers and risk of myocardial infarction: systematic review
    Michael A. McDonald, Scot H. Simpson, Justin Adrian Ezekowitz, Gabor Gyenes, Ross T. Tsuyuki · 2005 · BMJ
100. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials
     Swapnil S. Hiremath, Dean A. Fergusson, Nicholas A. Fergusson, Alexandria Bennett, Greg A. Knoll · 2016 · American Journal of Kidney Diseases